Hematologic Malignancies Program The goal of the Program in Hematologic Malignancies is to develop a better understanding and improved treatments for this group of diseases. Four areas of focus predominate: (1) Developing a deeper understanding of the biologic basis of hematologic malignancies; (2) Using this understanding to develop better non- transplant therapies; (3) Discovering novel methods to overcome the current limitations of hematopoietic cell transplantation; and (4) Using these discoveries to improve the actual practice of hematopoietic cell transplantation. The Hematologic Malignancies program currently has 75 members from 11 departments and 3 institutions. Seventy-three Members (97%) have peer-reviewed funding or are the Principal Investigator on a clinical trial. The Hematologic Malignancies program currently has $24.3M in grant funding (direct dollars) of which $16.9M is peer-reviewed and $6.9M (40%) is from NCI. The Program published a total of 1218 papers in the previous grant period. 27% were intra-programmatic, 35% were inter-programmatic and 19% were inter- institutional. In 2012, 148,040 Americans were diagnosed with a hematologic malignancy, resulting in 54,380 deaths, making these malignancies collectively the second leading cause of cancer death after lung cancer (160,340), and exceeding in aggregate the deaths from colon (51,690), breast (39,920) pancreas (37,390), and prostate cancer (28,170). Previous work from our program has improved our understanding of this group of diseases, particularly the myeloid malignancies, leading to new approaches to screening for genetic abnormalities, improved monitoring of disease progression and novel therapeutics. Results from our studies have also led to a better understanding of the science behind problems of hematopoietic cell transplantation and provided methods to overcome some of these problems leading to improved cure rates. Members of this program also oversee a very busy clinical service, caring for 802 new patients in 2013 alone, of which 466 (58%) were treated on clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617725
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications